A
AC Immune
Clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases
About AC Immune
AC Immune is a biopharmaceutical company specializing in the development of innovative therapies and diagnostics for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the biotechnology sector and primarily serves patients, healthcare providers, and pharmaceutical companies. AC Immune's business model revolves around leveraging its proprietary technology platforms to create a broad pipeline of products aimed at treating and diagnosing neurodegenerative conditions. The company generates revenue through partnerships, licensing agreements, and milestone payments from larger pharmaceutical firms. AC Immune's goal is to become a global leader in precision medicine for neurodegenerative diseases, addressing one of the most significant challenges facing society today.
Source: Dealroom company dataAt a glance
- Founded
- 2003
- Headquarters
- Lausanne, Switzerland
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning AC Immune.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
dievini Hopp Biotech holding
Dietmar Hopp
Avidity Partners
BVF Partners
Redmile Group
StemPoint Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
112 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about AC Immune on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AC Immune on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.